Two bleeding disorder treatments for both chronic and acute conditions, Qfitlia and Cablivi, have been approved in China.
Sanofi’s latest fair value estimate has been nudged down from €106.26 to €105.20 as analysts factor in slightly softer revenue growth assumptions, even as the company’s overall risk profile remains ...
With Qfitlia and Cablivi, Sanofi reaches its fourth and fifth approvals in China this year, following Tzield for stage 2 type ...
We recently published 13 Best ADR Stocks to Invest In. Sanofi (NASDAQ:SNY) is one of the best ADR stocks. Sanofi (NASDAQ:SNY) ...
Sanofi secures China approvals for Qfitlia and Cablivi, expanding its rare hematology portfolio with new options for ...
Sanofi (SNY) has received Chinese regulatory approval for two rare hematology drugs, Qfitlia and Cablivi, significantly ...
Rival European pharma giants Sanofi and GSK have both forged new partnerships to bolster their preclinical research. | Rival ...
Sanofi (NASDAQ:SNY) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Sanofi (NASDAQ:SNY) has ...
GlobalData on MSN
China’s NMPA approves Sanofi’s rare haematologic disease treatments
China’s National Medical Products Administration (NMPA) has granted approval for Sanofi’s rare haematologic disease ...
Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...
Sanofi (ENXTPA:SAN) has been drifting lower recently, and that slide is starting to catch investors attention as they weigh short term weakness against long term growth in vaccines, immunology, and ...
As an FDA official said that the agency has evidence that links COVID vaccines to the deaths of at least 10 children, the U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback